Loading...
EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer
Despite the success of treating EGFR mutant lung cancer patients with EGFR tyrosine kinase inhibitors (TKIs), all patients eventually acquire resistance to these therapies. Although various resistance mechanisms have been described, there are currently no FDA-approved therapies that target alternati...
Saved in:
| Published in: | Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2016
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4715957/ https://ncbi.nlm.nih.gov/pubmed/26744526 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-15-0717 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|